Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Rated “Reduce” by Sell-Side Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has been given a consensus recommendation of “Reduce” by the twenty-one brokerages that are covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $22.59.

SRPT has been the topic of a number of analyst reports. Weiss Ratings raised Sarepta Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Piper Sandler reduced their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a report on Thursday, July 9th. Needham & Company LLC reissued an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. JPMorgan Chase & Co. dropped their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, September 30th. Finally, HC Wainwright restated a “sell” rating and set a $5.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 5th.

Sarepta Therapeutics Trading Down 3.9%

Shares of SRPT opened at $17.10 on Tuesday. The company’s fifty day simple moving average is $19.29 and its 200-day simple moving average is $18.72. The company has a market cap of $1.81 billion, a P/E ratio of -5.90, a P/E/G ratio of 0.31 and a beta of 0.38. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. Sarepta Therapeutics has a twelve month low of $14.68 and a twelve month high of $24.68.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. The company had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. During the same period in the prior year, the firm posted $2.02 EPS. The firm’s revenue was down 34.3% compared to the same quarter last year. As a group, analysts expect that Sarepta Therapeutics will post 3.27 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in SRPT. Meeder Asset Management Inc. bought a new position in Sarepta Therapeutics in the second quarter worth approximately $27,000. Nykredit A S purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth $43,000. Ancora Advisors LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth $45,000. Allworth Financial LP bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth $58,000. Finally, Rockefeller Capital Management L.P. grew its position in shares of Sarepta Therapeutics by 98.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock worth $88,000 after buying an additional 2,034 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.